CA1211372A - Pharmacological compositions based on cisplatinum and method for obtaining same - Google Patents
Pharmacological compositions based on cisplatinum and method for obtaining sameInfo
- Publication number
- CA1211372A CA1211372A CA000437117A CA437117A CA1211372A CA 1211372 A CA1211372 A CA 1211372A CA 000437117 A CA000437117 A CA 000437117A CA 437117 A CA437117 A CA 437117A CA 1211372 A CA1211372 A CA 1211372A
- Authority
- CA
- Canada
- Prior art keywords
- cisplatinum
- freeze
- dried
- solution
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 21
- 239000008196 pharmacological composition Substances 0.000 title abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 238000004108 freeze drying Methods 0.000 claims abstract description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 15
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims abstract description 13
- 230000008569 process Effects 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 11
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims 2
- 239000000243 solution Substances 0.000 abstract description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 22
- 239000008215 water for injection Substances 0.000 abstract description 12
- 238000009472 formulation Methods 0.000 abstract description 11
- 239000007864 aqueous solution Substances 0.000 abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 3
- 239000011707 mineral Substances 0.000 abstract description 3
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 108091006629 SLC13A2 Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 238000004090 dissolution Methods 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 9
- 229930195725 Mannitol Natural products 0.000 description 9
- 238000013019 agitation Methods 0.000 description 9
- 235000010355 mannitol Nutrition 0.000 description 9
- 239000000594 mannitol Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000008227 sterile water for injection Substances 0.000 description 7
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000861718 Chloris <Aves> Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000219289 Silene Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229920005556 chlorobutyl Polymers 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT23396A/82 | 1982-09-23 | ||
| IT23396/82A IT1153974B (it) | 1982-09-23 | 1982-09-23 | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1211372A true CA1211372A (en) | 1986-09-16 |
Family
ID=11206716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000437117A Expired CA1211372A (en) | 1982-09-23 | 1983-09-20 | Pharmacological compositions based on cisplatinum and method for obtaining same |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US4670262A (enEXAMPLES) |
| JP (1) | JPS5978117A (enEXAMPLES) |
| AT (1) | AT382077B (enEXAMPLES) |
| AU (1) | AU559499B2 (enEXAMPLES) |
| BE (1) | BE897761A (enEXAMPLES) |
| CA (1) | CA1211372A (enEXAMPLES) |
| CH (1) | CH655852A5 (enEXAMPLES) |
| DE (1) | DE3333024A1 (enEXAMPLES) |
| DK (1) | DK157168C (enEXAMPLES) |
| FI (1) | FI78236C (enEXAMPLES) |
| FR (1) | FR2533439B1 (enEXAMPLES) |
| GB (1) | GB2127291B (enEXAMPLES) |
| GR (1) | GR79055B (enEXAMPLES) |
| IE (1) | IE56173B1 (enEXAMPLES) |
| IL (1) | IL69752A (enEXAMPLES) |
| IT (1) | IT1153974B (enEXAMPLES) |
| NL (1) | NL8303211A (enEXAMPLES) |
| SE (1) | SE464061B (enEXAMPLES) |
| SU (1) | SU1424722A3 (enEXAMPLES) |
| ZA (1) | ZA836904B (enEXAMPLES) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8303657A (nl) * | 1983-10-24 | 1985-05-17 | Pharmachemie Bv | Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan. |
| DK500185A (da) * | 1984-11-02 | 1986-05-03 | Johnson Matthey Plc | Oploeseliggjort platinforbindelse |
| JPH0665648B2 (ja) * | 1985-09-25 | 1994-08-24 | 塩野義製薬株式会社 | 白金系抗癌物質の安定な凍結真空乾燥製剤 |
| JP2524217B2 (ja) * | 1988-04-18 | 1996-08-14 | マルハ株式会社 | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤 |
| FI895340A7 (fi) * | 1988-11-14 | 1990-05-15 | Bristol Myers Squibb Co | Hypertoninen cisplatin-liuos |
| US20030148933A1 (en) * | 1990-10-01 | 2003-08-07 | Pharma Mar S.A. | Derivatives of dehydrodidemnin B |
| JPH06192109A (ja) * | 1992-09-04 | 1994-07-12 | Fuji Kagaku Kogyo Kk | 抗腫瘍効果増強剤 |
| FR2759293B1 (fr) * | 1997-02-11 | 1999-04-30 | Ethypharm Lab Prod Ethiques | Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie |
| GB9803448D0 (en) * | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| PT1229922E (pt) * | 1999-11-15 | 2007-09-12 | Pharma Mar Sa | Tratamento de cancros com aplidina. |
| UA76718C2 (uk) * | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| KR20030038812A (ko) * | 2000-10-12 | 2003-05-16 | 파르마 마르, 에스.에이. | 암 치료 방법 |
| AU2002243646B2 (en) | 2001-01-25 | 2006-06-22 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Formulation of boronic acid compounds |
| RU2178702C1 (ru) * | 2001-02-21 | 2002-01-27 | Общество с ограниченной ответственностью "Нобель" | Антираковое средство |
| JP4272991B2 (ja) * | 2001-09-21 | 2009-06-03 | 大日本住友製薬株式会社 | 凍結乾燥製剤 |
| US20050004012A1 (en) * | 2001-10-19 | 2005-01-06 | Ramon Mangues | Use of aplidine for the treatment of pancreatic cancer |
| RU2335294C2 (ru) * | 2003-03-12 | 2008-10-10 | Дана-Фарбер Кэнсер Инститьют, Инк. | Аплидин для лечения множественной миеломы |
| UA83022C2 (uk) * | 2003-03-12 | 2008-06-10 | Фарма Мар, С.А. | Аплідин для комбінованої терапії лейкозу та лімфоми |
| ATE347367T1 (de) * | 2003-10-13 | 2006-12-15 | Zoser B Salama | Pharmazeutische zusammensetzung umfassend oxoplatin und dessen salze |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| AU2007220050B2 (en) * | 2006-02-28 | 2013-08-29 | Pharma Mar, S.A. | Improved antitumoral treatments |
| AU2008313627A1 (en) * | 2007-10-19 | 2009-04-23 | Pharma Mar, S.A. | Improved antitumoral treatments |
| RU2010140888A (ru) * | 2008-03-07 | 2012-04-20 | Фарма Мар, С.А. (Es) | Улучшенные противораковые терапии |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| JP5670335B2 (ja) | 2008-09-25 | 2015-02-18 | セファロン、インク． | ベンダムスチン液体製剤 |
| CN107773538B (zh) * | 2016-08-27 | 2022-09-13 | 鲁南制药集团股份有限公司 | 稳定的甲啶铂无菌冻干粉末及其制备工艺 |
| JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1432562A (en) * | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum co-ordination compounds |
| GB1432563A (en) * | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum- co-ordination compounds |
| US4053587A (en) * | 1973-04-13 | 1977-10-11 | Research Corporation | Method of treating viral infections |
| US4255417A (en) * | 1976-08-04 | 1981-03-10 | Johnson Matthey, Inc. | Platinum compounds for the irradication of skin blemishes |
| SE445172B (sv) * | 1978-05-30 | 1986-06-09 | Bristol Myers Co | Stabil, steril vattenlosning av cisplatin i enhetsdoseringsform |
| US4273755A (en) * | 1979-08-16 | 1981-06-16 | Mpd Technology Corporation | Preparation of platinum complexes |
| US4302446A (en) * | 1979-10-02 | 1981-11-24 | Bristol-Myers Company | Pharmaceutical compositions |
| AU541056B2 (en) * | 1980-03-31 | 1984-12-13 | Bristol-Myers Company | Pharmaceuticals formulations |
| US4451447A (en) * | 1980-03-31 | 1984-05-29 | Bristol-Myers Company | Pharmaceutical formulations |
-
1982
- 1982-09-23 IT IT23396/82A patent/IT1153974B/it active
-
1983
- 1983-09-12 GB GB08324380A patent/GB2127291B/en not_active Expired
- 1983-09-13 SE SE8304920A patent/SE464061B/sv not_active IP Right Cessation
- 1983-09-13 DE DE3333024A patent/DE3333024A1/de not_active Withdrawn
- 1983-09-13 AU AU19089/83A patent/AU559499B2/en not_active Ceased
- 1983-09-13 AT AT0326283A patent/AT382077B/de active
- 1983-09-14 JP JP58168513A patent/JPS5978117A/ja active Pending
- 1983-09-15 CH CH5037/83A patent/CH655852A5/de not_active IP Right Cessation
- 1983-09-15 FI FI833300A patent/FI78236C/fi not_active IP Right Cessation
- 1983-09-15 SU SU833643499A patent/SU1424722A3/ru active
- 1983-09-15 GR GR72452A patent/GR79055B/el unknown
- 1983-09-15 BE BE0/211538A patent/BE897761A/fr not_active IP Right Cessation
- 1983-09-16 IE IE2172/83A patent/IE56173B1/en unknown
- 1983-09-16 FR FR8314772A patent/FR2533439B1/fr not_active Expired
- 1983-09-16 DK DK424383A patent/DK157168C/da not_active IP Right Cessation
- 1983-09-16 NL NL8303211A patent/NL8303211A/nl not_active Application Discontinuation
- 1983-09-16 IL IL69752A patent/IL69752A/xx unknown
- 1983-09-16 ZA ZA836904A patent/ZA836904B/xx unknown
- 1983-09-20 CA CA000437117A patent/CA1211372A/en not_active Expired
-
1985
- 1985-05-28 US US06/738,436 patent/US4670262A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| SE8304920L (sv) | 1984-03-24 |
| FI78236C (fi) | 1989-07-10 |
| ZA836904B (en) | 1984-10-31 |
| SE8304920D0 (sv) | 1983-09-13 |
| CH655852A5 (de) | 1986-05-30 |
| AU1908983A (en) | 1984-03-29 |
| SE464061B (sv) | 1991-03-04 |
| IT1153974B (it) | 1987-01-21 |
| IL69752A (en) | 1986-07-31 |
| GB2127291A (en) | 1984-04-11 |
| BE897761A (fr) | 1984-01-02 |
| AT382077B (de) | 1987-01-12 |
| DK424383A (da) | 1984-03-24 |
| IE832172L (en) | 1984-03-23 |
| DK157168C (da) | 1990-04-09 |
| SU1424722A3 (ru) | 1988-09-15 |
| US4670262A (en) | 1987-06-02 |
| GB2127291B (en) | 1986-01-15 |
| IL69752A0 (en) | 1983-12-30 |
| ATA326283A (de) | 1986-06-15 |
| GR79055B (enEXAMPLES) | 1984-10-02 |
| JPS5978117A (ja) | 1984-05-04 |
| FR2533439A1 (fr) | 1984-03-30 |
| FR2533439B1 (fr) | 1986-08-14 |
| GB8324380D0 (en) | 1983-10-12 |
| FI833300A7 (fi) | 1984-03-24 |
| DK424383D0 (da) | 1983-09-16 |
| DE3333024A1 (de) | 1984-03-29 |
| DK157168B (da) | 1989-11-20 |
| NL8303211A (nl) | 1984-04-16 |
| IT8223396A0 (it) | 1982-09-23 |
| IE56173B1 (en) | 1991-05-08 |
| FI78236B (fi) | 1989-03-31 |
| AU559499B2 (en) | 1987-03-12 |
| FI833300A0 (fi) | 1983-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1211372A (en) | Pharmacological compositions based on cisplatinum and method for obtaining same | |
| DE60035125T2 (de) | Konservierung von empfindlichem biologischen material | |
| NO332937B1 (no) | Frysetorket pantoprazol-preparat og fremgangs-mate ved fremstilling av det samme samt pantoprazol-injeksjonspreparat» slik at den omfatter en omtale av de ulike aspektene ved oppfinnelsen | |
| US5731291A (en) | Partially lyophilized fructose-1,6-diphosphate (FDP) for injection into humans | |
| US20120245230A1 (en) | Method and composition for preparing stable liquid formulations of paracetamol | |
| NO336427B1 (no) | Farmasøytisk sammensetning av vinflunin som er ment for parenteral administrering, fremstillingsmåte og anvendelse derav | |
| AU612037B2 (en) | Stable aqueous cisplatin solutions | |
| CZ2002291A3 (cs) | Farmaceuticky stabilní přípravek oxaliplatiny k parenterální aplikaci | |
| CA2117761C (en) | Pharmaceutical compositions containing il-6 | |
| CA2463681A1 (en) | Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent | |
| US4698361A (en) | Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same | |
| EP3718571A1 (en) | Compositions | |
| CY1159A (en) | Pharmaceutical dormulations containing cisplatinum(11)diamminedichloride | |
| NO176390B (no) | Fremgangsmåte for fremstilling av en stabil opplösning av rebeccamycin-analog | |
| CA1084842A (en) | Stabilized aminophylline solution and process therefor | |
| US4292312A (en) | Method for preparing alloxan stable aqueous solutions and solutions resulting therefrom | |
| US20060275331A1 (en) | Pharmaceutical composition, method of manufacturing and therapeutic use thereof | |
| JPH03130226A (ja) | １つより多いエチレンイミン基を有する抗新生物性化合物用の安定な製薬学的配合及び方法 | |
| EP1107750B1 (en) | Pharmaceutical composition with antitumor activity on the basis of carboplatin | |
| CA2537610A1 (en) | Pharmaceutical composition, method of manufacturing and therapeutic use thereof | |
| EP1691813B1 (en) | Ready-for-use injectable solution of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amine-1h-purin-6(9h)-one, sterile, stable; closed system for packing the solution, process for eliminating alkaline residuals of 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amine-1h-purin-6(9h)-one crystals; | |
| SU1213973A3 (ru) | Способ стабилизации антибактериальной щелочнометаллической соли 7В-(а-карбокси-а-арилацетамидо)-7 @ -метоксил-3-гетероциклотиометил-1-детиа-1-окса-3-цефем-4-карбоновой кислоты | |
| EP0814087A2 (en) | Partially lyophilized fructose-1,6-diphosphate (FDP) for injection into humans | |
| AU735359B2 (en) | Partially lyophilized fructose-1,6-diphosphate (FDP) for injection into humans | |
| CA2303786A1 (en) | Freeze-dried product and method for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |